Elutia (ELUT) investor relations material

Strategic focus and technology platform

• Specializes in combining antibiotic delivery with implantable biological matrices to address surgical site infections.

• Initial success with EluPro, an antibiotic-eluting envelope for pacemakers, led to an $88 million acquisition by Boston Scientific.

• Applying proven technology to breast reconstruction, a larger market with higher infection rates.

• Technology platform is established, FDA-cleared, and supported by a fully resourced team and manufacturing facility.

• Plans to divest non-core products to further strengthen the balance sheet.

Market opportunity and clinical need

• Breast reconstruction represents a $1.5 billion U.S. market with 162,000 surgeries annually, 85% using biological mesh.

• Postoperative infection rates in breast reconstruction are 15%-20%, significantly higher than in pacemaker implants.

• Surgical site infections add $10 billion in costs annually and are non-reimbursable for hospitals.

• Current biological meshes are inert and do not address infection risk.

• Local antibiotic delivery is critical due to loss of blood supply after mastectomy, making systemic antibiotics ineffective.

Product development and commercialization timeline

• NXT-41, the base matrix, is submitted for FDA approval with clearance expected in Q4 this year.

• NXT-41X, the drug-eluting version, targets FDA approval in the first half of next year.

• Targeted product launch planned for the second half of next year.

• Automated GMP facility in Maryland supports efficient, scalable production.

• Commercialization strategy leverages concentrated market, focusing on top hospitals for rapid adoption.